Christina Y. Weng: Power List Perspectives

Christina Y. Weng, a leading professor in ophthalmology at Baylor College of Medicine, highlights the surge in advancements within retina treatment, including the recent approval of the first treatment for macular telangiectasia type 2 and innovations like gene therapy and AI-assisted imaging technologies. As therapies evolve, personalized medicine is anticipated to play a crucial role in tailoring treatments based on individual disease profiles, potentially transforming care for common and orphan retinal diseases. The future is bright with ongoing clinical trials paving the way for individualized patient care.

About the Author(s)

Julian Upton

Julian Upton is Group Editor of The Ophthalmologist and The New Optometrist. With 20+ years' experience of the magazine industry, he has covered many facets of science and healthcare.

More Articles by Julian Upton